ATE362991T1 - Kondensierte plasmid-liposome komplex zur transfektion - Google Patents

Kondensierte plasmid-liposome komplex zur transfektion

Info

Publication number
ATE362991T1
ATE362991T1 AT98949342T AT98949342T ATE362991T1 AT E362991 T1 ATE362991 T1 AT E362991T1 AT 98949342 T AT98949342 T AT 98949342T AT 98949342 T AT98949342 T AT 98949342T AT E362991 T1 ATE362991 T1 AT E362991T1
Authority
AT
Austria
Prior art keywords
transfection
plasmid
liposome complex
selecting
condensed plasmid
Prior art date
Application number
AT98949342T
Other languages
English (en)
Inventor
Shi Huang
Edwin Oto
Mohammad Hassanipour
Bei Jin
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE362991T1 publication Critical patent/ATE362991T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT98949342T 1997-03-28 1998-09-11 Kondensierte plasmid-liposome komplex zur transfektion ATE362991T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/827,236 US5851818A (en) 1996-05-31 1997-03-28 Condensed plasmid-liposome complex for transfection
PCT/US1998/019067 WO2000015825A1 (en) 1997-03-28 1998-09-11 Condensed plasmid-liposome complex for transfection

Publications (1)

Publication Number Publication Date
ATE362991T1 true ATE362991T1 (de) 2007-06-15

Family

ID=26794355

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949342T ATE362991T1 (de) 1997-03-28 1998-09-11 Kondensierte plasmid-liposome komplex zur transfektion

Country Status (9)

Country Link
US (1) US5851818A (de)
EP (1) EP1109926B1 (de)
JP (1) JP2002525270A (de)
AT (1) ATE362991T1 (de)
AU (1) AU9568698A (de)
CA (1) CA2342292A1 (de)
DE (1) DE69837819T2 (de)
ES (1) ES2286857T3 (de)
WO (1) WO2000015825A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5851818A (en) * 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US6133026A (en) * 1996-05-31 2000-10-17 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
JP2001510457A (ja) 1996-11-12 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インビボ送達に有効な、脂質―核酸複合体の安定な製剤の調製
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
PT1811036E (pt) * 1999-02-22 2011-07-11 Univ Georgetown Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes
US7112337B2 (en) * 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US20020006664A1 (en) * 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
CA2383423A1 (en) * 1999-09-17 2001-03-22 Whitehead Institute For Biomedical Research Reverse transfection method
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US8143195B2 (en) * 2000-01-24 2012-03-27 Yingjian Wang Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays
US7429466B2 (en) * 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
WO2003000291A1 (fr) * 2001-06-22 2003-01-03 Techno Network Shikoku Co., Ltd. Vesicules lipidiques, processus de production de vesicules lipidiques et procede d'immobilisation de gene sur ces vesicules lipidiques
US6670129B2 (en) 2001-09-24 2003-12-30 Corning Incorporated Cell transfection apparatus and methods for making and using the cell transfection apparatus
AU2003237864B2 (en) * 2002-05-15 2008-12-18 California Pacific Medical Center Delivery of nucleic acid-like compounds
SG172476A1 (en) * 2002-08-12 2011-07-28 Dynavax Tech Corp Immunomodulatory compositions comprising a cationic condensing agent, an immunostimulatory compound comprising 5'-cg-3', an a non ionic detergent
WO2004089339A2 (en) 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
JP2007512355A (ja) * 2003-11-21 2007-05-17 アルザ コーポレイション 開裂性のｐｅｇで表面修飾されたリポソーム−ｄｎａ複合体で媒介される遺伝子送達
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
JP4919397B2 (ja) * 2006-06-30 2012-04-18 北海道システム・サイエンス株式会社 核酸導入用組成物
JP4510842B2 (ja) * 2007-03-26 2010-07-28 キヤノン株式会社 ポリヒドロキシアルカノエート被覆リポソーム
AU2014233428B2 (en) 2013-03-15 2019-09-19 Loma Linda University Treatment of autoimmune diseases
RU2589280C1 (ru) * 2015-02-09 2016-07-10 Государственное автономное научное учреждение Республики Башкортостан "Центр аграрных исследований" Средство с липосомами, содержащими глутаминовую кислоту и экстракт прополиса, обладающее ноотропной активностью
CN109288794B (zh) * 2018-11-19 2021-02-23 上海交通大学 一种蜂毒素脂质体纳米制剂及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187260A (en) * 1988-09-06 1993-02-16 Sharifa Karali Process for the preparation of a high purity protamine-DNA complex and process for use of same
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5851818A (en) * 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection

Also Published As

Publication number Publication date
EP1109926A1 (de) 2001-06-27
WO2000015825A1 (en) 2000-03-23
AU9568698A (en) 2000-04-03
EP1109926B1 (de) 2007-05-23
US5851818A (en) 1998-12-22
DE69837819T2 (de) 2008-01-31
CA2342292A1 (en) 2000-03-23
ES2286857T3 (es) 2007-12-01
JP2002525270A (ja) 2002-08-13
DE69837819D1 (de) 2007-07-05
HK1039633A1 (en) 2002-05-03

Similar Documents

Publication Publication Date Title
DE69837819D1 (de) Kondensierte plasmid-liposome komplex zur transfektion
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
WO2000003683A3 (en) Liposomal encapsulated nucleic acid-complexes
ATE322255T1 (de) Polyamid-oligomere
EA199900715A1 (ru) Липидные комплексы и липосомы совершенно нерастворимых комплексов платины
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
WO1997030024A3 (de) Lipidverbindungen und deren verwendung z.b. in liposomen
ATE273320T1 (de) Fusogene liposomen
PL351487A1 (en) Encapsulation of bioactive complexes in liposomes
ATE207738T1 (de) Verfahren zur baladung von lipidvesikeln
ATE238038T1 (de) Liposomale formulierungen von mitoxantron
ATE272393T1 (de) Rekonstruktion gereinigter membranproteine in vorgefertigten liposomen
MXPA02012068A (es) Formulaciones liposomales inhibidoras de la timidilato de benzoqunazolina sintasa.
DE69926615D1 (de) Lipidabkömmlinge von pentaerythritol
DE60110057D1 (de) Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung
WO2001049266A3 (en) Iron chelator delivery system
PT1135193E (pt) Agentes para o tratamento de tumores a base de lipossomas e compreendendo tamoxifeno
ATE272648T1 (de) Glycokonjugate von 20(s)-camptothecin
DE60041351D1 (de) Gssytem
GB0020331D0 (en) Enzyme
PT938584E (pt) Processo para o fabrico do ácido (s)-3,3,3-trifluoro-2-hidroxi-2-metilpropiónico ou (r)-3,3,3-trifluoro-2-hidroxi-2-metilpropiónico
HK1041450A1 (zh) 脂质体合成物和放射致敏剂的施药方法
WO2001078785A3 (de) Wirkstoff-konjugate mit intrazellulär wirksamen liganden
BR9811579B1 (pt) ácidos 3-ciano-2,4-dialógeno-5-fluorobenzóicos e processo para a preparação dos mesmos.
FI933506A0 (fi) Bicyklopolyazamakrocyklokarboxylsyrakomplex, konjugat daerav, foerfarande foer deras framstaellning och anvaendning som kontrastmedel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties